Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

177 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†.
Gourgou-Bourgade S, Cameron D, Poortmans P, Asselain B, Azria D, Cardoso F, A'Hern R, Bliss J, Bogaerts J, Bonnefoi H, Brain E, Cardoso MJ, Chibaudel B, Coleman R, Cufer T, Dal Lago L, Dalenc F, De Azambuja E, Debled M, Delaloge S, Filleron T, Gligorov J, Gutowski M, Jacot W, Kirkove C, MacGrogan G, Michiels S, Negreiros I, Offersen BV, Penault Llorca F, Pruneri G, Roche H, Russell NS, Schmitt F, Servent V, Thürlimann B, Untch M, van der Hage JA, van Tienhoven G, Wildiers H, Yarnold J, Bonnetain F, Mathoulin-Pélissier S, Bellera C, Dabakuyo-Yonli TS. Gourgou-Bourgade S, et al. Ann Oncol. 2015 May;26(5):873-879. doi: 10.1093/annonc/mdv106. Epub 2015 Feb 27. Ann Oncol. 2015. PMID: 25725046 Free article. Review.
Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French multicentre GEFPICS study.
Vincent-Salomon A, MacGrogan G, Couturier J, Arnould L, Denoux Y, Fiche M, Jacquemier J, Mathieu MC, Penault-Llorca F, Rigaud C, Roger P, Treilleux I, Vilain MO, Mathoulin-Pélissier S, Le Doussal V. Vincent-Salomon A, et al. Histopathology. 2003 Apr;42(4):337-47. doi: 10.1046/j.1365-2559.2003.01598.x. Histopathology. 2003. PMID: 12653945
Time for reappraisal of progesterone-receptor testing in breast cancer management.
MacGrogan G, de Mascarel I, Sierankowski G, Mauriac L, Debled M, Durand M, De Lara CT, Avril A, Picot V, Mathoulin-Pélissier S. MacGrogan G, et al. J Clin Oncol. 2005 Apr 20;23(12):2870-1; author reply 2871. doi: 10.1200/JCO.2005.05.241. J Clin Oncol. 2005. PMID: 15838009 No abstract available.
Impact of immunohistochemical markers, CK5/6 and E-cadherin on diagnostic agreement in non-invasive proliferative breast lesions.
MacGrogan G, Arnould L, de Mascarel I, Vincent-Salomon A, Penault-Llorca F, Lacroix-Triki M, Bibeau F, Baranzelli MC, Fridman V, Antoine M, Bécette V, Brouste V, Jacquemier J, Mathoulin-Pélissier S; GEFPICS group. MacGrogan G, et al. Histopathology. 2008 May;52(6):689-97. doi: 10.1111/j.1365-2559.2008.03016.x. Epub 2008 Apr 5. Histopathology. 2008. PMID: 18397281
177 results